Home › Trials › NCT07025642
Clinical trial Recruiting at 1 site Interventional Ages 30 to 100 Women only

Mirabegron, solifenacin, combined therapy, and Botox for women with overactive bladder in Taiwan

Official title: Outcome of Different Treatments of Overactive Bladder in Taiwan

Run by Mackay Medical College · NCT07025642 · Data updated 2026-11-12

This will test whether mirabegron, solifenacin, their combination, or intradetrusor Botox reduce the bladder's mechanical work and change bladder compliance in women with overactive bladder.

More Overactive Bladder (OAB) trials

Quick facts

Study typeInterventional
Ages30 Years to 100 Years
SexWomen only
Enrollment60 (estimated)
SponsorMackay Medical College
Academic / other
Locations1 site (New Taipei City)
StatusRecruiting
StartedJuly 1, 2025
Main results expectedMay 1, 2026
Study endsDecember 1, 2026
Registry record updatedJune 17, 2025
Trial IDNCT07025642 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Women with overactive bladder who can undergo urodynamic testing and who do not have diabetes, cerebrovascular disease, or other excluded medical conditions are ideal candidates.

Probably not a fit

Patients with diabetes, prior stroke, other excluded comorbidities, men, or those with neurogenic bladder are unlikely to be eligible and may not benefit from the study's findings.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center interventional study in New Taipei City applies pressure-volume analysis (PVA), a thermodynamic method adapted from cardiology, to quantify bladder mechanical work per void and to visualize compliance dynamics. Women with overactive bladder will undergo standardized urodynamic evaluations before and after treatment with mirabegron, solifenacin, combined mirabegron+solifenacin, or intradetrusor botulinum toxin A. The study compares changes in PVA-derived work and compliance metrics across treatments to determine how each therapy affects storage and voiding energetics. Patients with diabetes, prior stroke, or other significant comorbidities are excluded to reduce confounding.

Why it matters

Potential benefit: If successful, this could identify which therapy best lowers bladder mechanical workload and improves storage function, helping clinicians choose treatments that reduce symptoms and protect bladder health.

How similar studies have gone: Existing trials show symptomatic benefit for antimuscarinics, beta-3 agonists, and botulinum toxin, but using pressure-volume thermodynamic analysis to quantify bladder work and compliance is a novel and largely untested approach.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

\- female overactive bladder

Exclusion Criteria:

* DM, CVA, other medical problems

Where it's running

  • Department of Obstetrics and Gynecology
    New Taipei City, Taiwan     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Overactive Bladder (OAB) 19Mackay Medical College 6
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.